Navigation Links
ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma

STRIBUTION PROGRAM. THIS PROGRAM IS CALLED "RevAssist(R)". UNDER THIS PROGRAM, ONLY PRESCRIBERS AND PHARMACISTS REGISTERED WITH THE PROGRAM CAN PRESCRIBE AND DISPENSE THE PRODUCT. IN ADDITION, REVLIMID(R) (lenalidomide) MUST ONLY BE DISPENSED TO PATIENTS WHO ARE REGISTERED AND MEET ALL THE CONDITIONS OF THE RevAssist(R) PROGRAM.

2. HEMATOLOGIC TOXICITY (NEUTROPENIA AND THROMBOCYTOPENIA).

THIS DRUG IS ASSOCIATED WITH SIGNIFICANT NEUTROPENIA AND THROMBOCYTOPENIA. EIGHTY PERCENT OF PATIENTS WITH DEL 5q MYELODYSPLASTIC SYNDROMES HAD TO HAVE A DOSE DELAY/REDUCTION DURING THE MAJOR STUDY. THIRTY-FOUR PERCENT OF PATIENTS HAD TO HAVE A SECOND DOSE DELAY/REDUCTION. GRADE 3 OR 4 HEMATOLOGIC TOXICITY WAS SEEN IN 80% OF PATIENTS ENROLLED IN THE STUDY. PATIENTS ON THERAPY FOR DEL 5q MYELODYSPLASTIC SYNDROMES SHOULD HAVE THEIR COMPLETE BLOOD COUNTS MONITORED WEEKLY FOR THE FIRST 8 WEEKS OF THERAPY AND AT LEAST MONTHLY THEREAFTER. PATIENTS MAY REQUIRE DOSE INTERRUPTION AND/OR REDUCTION. PATIENTS MAY REQUIRE USE OF BLOOD PRODUCT SUPPORT AND/OR GROWTH FACTORS. (SEE DOSAGE AND ADMINISTRATION)

3. DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM.

This drug has demonstrated a significantly increased risk of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients with multiple myeloma who were treated with REVLIMID(R) (lenalidomide) combination therapy. Patients and physicians are advised to be observant for the signs and symptoms of thromboembolism. Patients should be instructed to seek medical care if they develop symptoms such as shortness of breath, chest pain, or arm or leg swelling. It is not known whether prophylactic anticoagulation or antiplatelet therapy prescribed in conjunction with REVLIMID(R) (lenalidomide) may lessen the potential for venous thromboembolic events. The decision to take prophylactic measures should be done carefully after an assessment of an individual patient's underlying risk factors.

You can get information abo
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:9/19/2014)... , September 19, 2014 ... IQ den äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, der jetzt ... interaktive PDF, verfügbar unter pharmaserialisation.com , zeigt ... sie jeweils in Kraft treten. Für ... nicht länger um das "ob", sondern darum, "wann" ...
(Date:9/19/2014)... , Sept. 19, 2014  CytRx Corporation (Nasdaq: ... company specializing in oncology, today announced that David ... at BioCentury,s 2014 NewsMakers in the Biotech Industry Conference on ... Time. The conference will take place at the Millennium ... . A live and archived webcast of ...
(Date:9/19/2014)... Sept. 19, 2014  PCI is pleased to ... Biotec is a leading provider of Clinical Trial ... Bridgend, Wales in the ... significantly expands PCI,s presence in the UK/EU to ... adding packaging, storage and distribution capacity, as well ...
Breaking Medicine Technology:Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3PCI Announces Acquisition Of Biotec 2PCI Announces Acquisition Of Biotec 3PCI Announces Acquisition Of Biotec 4PCI Announces Acquisition Of Biotec 5PCI Announces Acquisition Of Biotec 6
... ORANGE COUNTY, Calif., Sept. 8 Beckman Coulter, Inc. (NYSE: ... of products that simplify, automate, and innovate complex biomedical testing, ... conferences: Morgan Stanley 2010 Healthcare Conference on Monday, ... City, New York. Stifel Nicolaus 2010 Healthcare Conference on ...
... SAN MARINO, Calif., Sept. 7 Epeius Biotechnologies Corporation, ... medicine, reports the publication of a landmark paper in ... I/II clinical trials of Rexin-G in chemo-resistant metastatic pancreatic ... gained both Orphan Drug and FDA Fast Track Status, ...
Cached Medicine Technology:Beckman Coulter to Present at Upcoming Healthcare Conferences 2To Reach, Perchance to Kill the Cancer: A Soliloquy From Epeius Nanotechnologies Opposes That 'Sea of Troubles' 2
(Date:9/21/2014)... UNIWIGS, one of the leading online stores ... pieces, offers a line of human hair lace wigs inspired ... also shows people what the latest celebrity hairstyles ... there are 4 different hairstyles to choose from: a style ... lace wigs and a hot ombre red lace wig. People ...
(Date:9/21/2014)... More than a quarter of house fires are ... of two ways. The first type of dryer fire occurs ... type of dryer fire occurs when lint builds up in the ... due to malfunctioning electrical systems so if it doesn’t appear to ... Here are some ways that you can prevent dryer fires. , ...
(Date:9/21/2014)... (PRWEB) September 21, 2014 Expert witness ... released the findings from its 2014 Expert Witness Fees ... increasingly complex, the demand and compensation for qualified and ... in the Survey’s 16-year history. , The nearly ... hour for their expert work, an increase of 3.2% ...
(Date:9/21/2014)... "I wanted to be able to ... sugary, foul-tasting energy drinks," said an inventor from Fresh ... to drink plain, old coffee. That is why I ... developed ENERG CHEWING GUM to provide a healthy energy ... formula contains nutritious vitamins, minerals and antioxidants. It also ...
(Date:9/21/2014)... "I want to help people who are having ... money for chiropractors," said an inventor from St. Amat, ... for myself." , The Stretch is a device that ... and align the spine properly. It improves flexibility and ... nerves. Compact and easy to use, it's ideal for ...
Breaking Medicine News(10 mins):Health News:UniWigs New Arrivals Just In- Human Hair Lace Wigs Inspired By Famous Celebrities 2Health News:Restoration Local Offers Tips to Avoid Dryer Fires 2Health News:Restoration Local Offers Tips to Avoid Dryer Fires 3Health News:ExpertPages 2014 Survey Reports Expert Witness Hourly Fees Record All-Time Highs as Demand for Qualified Experts Continues to Grow 2
... of deadly neuroectodermal tumors , MONDAY, Dec. 7 (HealthDay ... role in a particularly aggressive type of childhood brain ... tumors (CNS-PNETs), the discovery of these oncogenes may lead ... , "Lack of insight into the molecular pathogenesis of ...
... , , SAN FRANCISCO, Dec. 7 Senior advocacy organizations ... grant from Verizon on Tuesday (Dec. 8) to continue the Commitment to End Abuse ... Hank Lacayo, president and CEO, Congress of California Seniors, ... and CEO, Self-Help for the Elderly, ...
... , GREENDALE, Wis., Dec. 7 Taste of Home ... Comfort Food Diet Cookbook, featuring America,s favorite comfort recipes with ... Food Diet Cookbook , on shelves December 31, 2009, is a ... pounds without feeling deprived. Enjoy pizza, lasagna, mac-n-cheese, pulled pork and ...
... ― The second-generation proteasome inhibitor carfilzomib is showing noteworthy ... among multiple myeloma patients in a phase II clinical ... of the American Society of Hematology. The updated ... relapsed or resistant multiple myeloma who have received one ...
... ... dental emergency, finding a qualified, experienced dentist is a crucial step in preserving your smile ... Minneapolis, ... stand against the high prices and inconvenience of emergency dental procedures. Whether a tooth is ...
... fewer hassles, study finds , MONDAY, Dec. 7 (HealthDay News) ... just as effective in preventing dangerous venous clots as an ... to manage, a new study finds. , Dabigatran is marketed ... not yet approved for use in the United States. , ...
Cached Medicine News:Health News:New Target May Be Eyed in Kids' Brain Cancer 2Health News:The Country's Largest Cooking Magazine Announces The Comfort Food Diet Cookbook 2Health News:The Country's Largest Cooking Magazine Announces The Comfort Food Diet Cookbook 3Health News:Drug shows positive responses, low side-effects in multiple myeloma 2Health News:Minneapolis Dentists, Shamblott Family Dentistry, Ease the Pain and Cost of Emergency Dental Procedures 2Health News:New Blood Thinner Could Replace Warfarin to Fight Venous Clots 2Health News:New Blood Thinner Could Replace Warfarin to Fight Venous Clots 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: